Chemical messenger in brain could point to better treatments for anxiety

Summary: Corticotropin-releasing factor and neuropeptide Y work in synchronized opposition to each other to remodel and rewire neurons in the amygdala as a response to stress. The process, researchers say, can be manually reversed to help relieve anxiety.

Source: University of Alberta

New research by a University of Alberta neuroscientist reveals more about how the mechanism the brain uses to regulate our response to stress could lead to better treatments for anxiety.

Bill Colmers and his team discovered that two chemical messengers—corticotropin-releasing factor (CRF) and neuropeptide Y (NPY)—work in a synchronized opposition to one another to remodel and rewire neurons in a part of the brain responsible for emotions, called the amygdala, as part of the body’s natural response to stress.

The research not only shows the change is occurring in the amygdala, but also reveals the process can be manually reversed, said Colmers.

“Anxiety disorders represent a huge unmet medical need. Any new information we can gather in relation to understanding the mechanisms involved with anxiety provides new targets for possible drug development,” said the U of A professor of pharmacology.

Where senses meet memories

The amygdala is a small, almond-shaped structure in the brain where information from our senses is combined with our memories and experiences.

“When you see a car, it’s just a car—unless you were previously T-boned by a red convertible. Then, thanks to your amygdala, that red convertible will elicit negative feelings in you,” explained Colmers.

“We see abnormal functioning in the amygdala in individuals who suffer from conditions such as anxiety, depression and post-traumatic stress disorder. It’s an interesting part of the brain that’s responsible for many essential processes, and it’s where we see the NPY and CRF in action.”

Better control

In previous research, Colmers’ team showed that NPY reduced anxiety in rats. Repeated exposure to NPY made the animals more resilient to stress for weeks or even months, and the team was able to identify the exact mechanism that elicits this response.

Building on this research, Colmers’ team observed that the body’s ability to react to a stress or threat is the result of CRF increasing the number and length of dendrites (or branches) found in neurons located in the amygdala. The lengthening and expansion of the neural network allows the brain to increase its signaling power and trigger the rest of the body to get ready to respond.

But the longer and more often our brains are in hyperdrive, which makes us feel anxious, the more difficult it is to get back to a healthy state.

This shows a head
The NPY has the opposite effect of CRF and reduces or shrinks the number and length of the dendrites, effectively telling the brain to “stand down” from the alert and let the body relax. Image is in the public domain.

Because it’s harmful for our bodies to be in this amped-up state for too long, NPY is normally released in our brains once the perceived threat has passed.

The NPY has the opposite effect of CRF and reduces or shrinks the number and length of the dendrites, effectively telling the brain to “stand down” from the alert and let the body relax.

Colmers’ research also revealed that one of the first steps in getting back to this relaxed state begins when NPY binds with the Y5 receptor, which occurs on the surface of a neuron. This binding activates the pathway that reconfigures the dendrites. According to Colmers, understanding each step in the pathway is important because each represents a potential target for drug development.

“My research areas have varied throughout my career and included anxiety, obesity, cachexia and energy balance. However, the common thread that has run through all of it is my friend neuropeptide Y,” said Colmers.

“While we definitely answered some of our questions with this latest study, it also revealed new questions, as the work was only conducted in male rats. The very important next question is whether this works the same in females.”

Colmers, a member of the Neuroscience and Mental Health Institute, and his collaborator Janice Urban from the Rosalind Franklin University of Medicine and Science, published the study, “Contribution of NPY Y5 Receptors to the Reversible Structural Remodeling of Basolateral Amygdala Dendrites in Male Rats Associated With NPY-Mediated Stress Resilience,” in the Journal of Neuroscience.

About this neuroscience research article

Source:
University of Alberta
Media Contacts:
University of Alberta Media Relations – University of Alberta
Image Source:
The image is in the public domain.

Original Research: Open access
“Contribution of NPY Y5 Receptors to the Reversible Structural Remodeling of Basolateral Amygdala Dendrites in Male Rats Associated with NPY-Mediated Stress Resilience”. by Sheldon D. Michaelson et al.
Journal of Neuroscience doi:10.1523/JNEUROSCI.2621-19.2020

Abstract

Contribution of NPY Y5 Receptors to the Reversible Structural Remodeling of Basolateral Amygdala Dendrites in Male Rats Associated with NPY-Mediated Stress Resilience

Endogenous neuropeptide Y (NPY) and corticotrophin-releasing factor (CRF) modulate the responses of the basolateral amygdala (BLA) to stress and are associated with the development of stress resilience and vulnerability, respectively. We characterized persistent effects of repeated NPY and CRF treatment on the structure and function of BLA principal neurons in a novel organotypic slice culture (OTC) model of male rat BLA, and examined the contributions of specific NPY receptor subtypes to these neural and behavioral effects. In BLA principal neurons within the OTCs, repeated NPY treatment caused persistent attenuation of excitatory input and induced dendritic hypotrophy via Y5 receptor activation; conversely, CRF increased excitatory input and induced hypertrophy of BLA principal neurons. Repeated treatment of OTCs with NPY followed by an identical treatment with CRF, or vice versa, inhibited or reversed all structural changes in OTCs. These structural responses to NPY or CRF required calcineurin or CaMKII, respectively. Finally, repeated intra-BLA injections of NPY or a Y5 receptor agonist increased social interaction, a validated behavior for anxiety, and recapitulated structural changes in BLA neurons seen in OTCs, while a Y5 receptor antagonist prevented NPY’s effects both on behavior and on structure. These results implicate the Y5 receptor in the long-term, anxiolytic-like effects of NPY in the BLA, consistent with an intrinsic role in stress buffering, and highlight a remarkable mechanism by which BLA neurons may adapt to different levels of stress. Moreover, BLA OTCs offer a robust model to study mechanisms associated with resilience and vulnerability to stress in BLA.

SIGNIFICANCE STATEMENT

Within the basolateral amygdala (BLA), neuropeptide Y (NPY) is associated with buffering the neural stress response induced by corticotropin releasing factor, and promoting stress resilience. We used a novel organotypic slice culture model of BLA, complemented with in vivo studies, to examine the cellular mechanisms associated with the actions of NPY. In organotypic slice cultures, repeated NPY treatment reduces the complexity of the dendritic extent of anxiogenic BLA principal neurons, making them less excitable. NPY, via activation of Y5 receptors, additionally inhibits and reverses the increases in dendritic extent and excitability induced by the stress hormone, corticotropin releasing factor. This NPY-mediated neuroplasticity indicates that resilience or vulnerability to stress may thus involve neuropeptide-mediated dendritic remodeling in BLA principal neurons.

Feel Free To Share This Neuroscience News.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.